Lipella Pharmaceuticals Stock (NASDAQ:LIPO)
Previous Close
$0.51
52W Range
$0.48 - $7.31
50D Avg
$0.59
200D Avg
$1.81
Market Cap
$2.36M
Avg Vol (3M)
$6.39K
Beta
-0.05
Div Yield
-
LIPO Company Profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.